TET1 and breast cancer: TET1 promoter is methylated in T47D, MDA-MB-453, MCF-7, MDA-MB-231, and YCC9-B1 BC cells, and the treatment with 5-azacytidine (5-aza) and Trichostatin A (TSA) decreases the methylation in the TET1 promoter, which promotes an increase in its expression in MDA-MB-231 BC cells [34,37,44,64].